US FDA Commissioner launches PREDICT ' a new system for assessing imported drugs risks

8 February 2010

US Food and Drug Administration Commissioner Margaret Hamburg last week announced the launch of a new risk-assessment tool to ensure the safety of imported drugs and food. The web-based PREDICT (the Predictive Risk-Based Evaluation for Dynamic Import Compliance Targeting ) system will rank the risk hazards of food and drugs as they enter the country and allow inspectors to focus on the most likely threats to public health.

FDA's new PREDICT risk-based screening system for imports will replace the admissibility screening function of OASIS, the FDA's legacy system. PREDICT will assist entry reviewers in targeting higher-risk shipments for examination. It will also expedite the clearance of lower-risk cargo, but only if accurate and complete data are provided by importers and entry filers.

Launching the project before a meeting at the Center for Strategic and International Studies, Commissioner Hamburg noted that up to 40% of the drugs Americans take are imported, and up to 80% of the active pharmaceutical ingredients in those drugs come from foreign sources. So we are definitely talking about real numbers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical